Diabetes
Conference Coverage
VERTIS CV: Ertugliflozin’s proven benefits fall short of other SGLT2 inhibitors
Added analyses from ertugliflozin’s cardiovascular outcome trial hint at SGLT2 inhibitor–consistent benefits, but proven benefits remain scant.
Conference Coverage
No prior use of insulin predicts postsurgical diabetes remission
No insulin use before bariatric surgery was associated with sustained diabetes remission 10 years later in patients with type 2 diabetes.
Conference Coverage
Once-weekly insulin data published; could alter treatment
Phase 2 data for Novo-Nordisk’s novel once-weekly basal insulin analog icodec, first presented earlier this year, are simultaneously published in...
Conference Coverage
For better, for worse? Couples’ lifestyles impact diabetes risk
Diet and physical activity levels are shared risk factors for type 2 diabetes between spouses. Biological factors are less closely associated with...
Med Tech Report
Smart health devices – promises and pitfalls
Major advancements in medical monitoring technology are now enabling physicians to get much deeper insight into their patients’ health status.
Conference Coverage
Vascular dementia risk particularly high in type 2 diabetes
A 35% higher risk for vascular dementia was seen in people with type 2 diabetes versus those without; other dementia types were increased or...
Conference Coverage
Survival after kidney transplantation lags in diabetes patients
Overall U.S. survival after kidney transplantation rose during 2000-2018, but less so in patients with type 1 or type 2 diabetes.
From the Journals
‘Dose response’ between exercise and improvement in diabetes
As adherence to a thrice-weekly, supervised exercise class rose, A1c levels fell. Aerobic exercise, or a combination of aerobic and resistance...
From the Journals
Pesco-Mediterranean diet, fasting ‘ideal’ to reduce CVD risk
Adhering to the Mediterranean diet and limiting eating time can lower the risk for cardiovascular disease.
Conference Coverage
Type 2 diabetes drugs and their use are top of EASD agenda
The virtual 2020 meeting of the European Association for the Study of Diabetes will feature new data and insights on SGLT2 inhibitors and GLP-1...
Conference Coverage
Novel calculator predicts cancer risk in patients with CVD
Individual lifetime total cancer risk ranges from 1% to 52%.